DE69837324D1 - Behandlung der multiplen sklerose durch einnahme von copolymer-1 - Google Patents

Behandlung der multiplen sklerose durch einnahme von copolymer-1

Info

Publication number
DE69837324D1
DE69837324D1 DE69837324T DE69837324T DE69837324D1 DE 69837324 D1 DE69837324 D1 DE 69837324D1 DE 69837324 T DE69837324 T DE 69837324T DE 69837324 T DE69837324 T DE 69837324T DE 69837324 D1 DE69837324 D1 DE 69837324D1
Authority
DE
Germany
Prior art keywords
treatment
copolymer
multiple sclerosis
ingestion
inhalation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69837324T
Other languages
English (en)
Other versions
DE69837324T2 (de
Inventor
Ruth Arnon
Michael Sela
Dvora Teitelbaum
Adrian Gilbert
Milka Linenberg
Rivka Riven-Kreitman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of DE69837324D1 publication Critical patent/DE69837324D1/de
Application granted granted Critical
Publication of DE69837324T2 publication Critical patent/DE69837324T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Peptides Or Proteins (AREA)
  • General Preparation And Processing Of Foods (AREA)
DE69837324T 1997-01-10 1998-01-12 Behandlung der multiplen sklerose durch einnahme von copolymer-1 Expired - Lifetime DE69837324T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL11998997 1997-01-10
IL11998997A IL119989A0 (en) 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis
PCT/US1998/000375 WO1998030227A1 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1

Publications (2)

Publication Number Publication Date
DE69837324D1 true DE69837324D1 (de) 2007-04-26
DE69837324T2 DE69837324T2 (de) 2007-11-29

Family

ID=11069682

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69837324T Expired - Lifetime DE69837324T2 (de) 1997-01-10 1998-01-12 Behandlung der multiplen sklerose durch einnahme von copolymer-1

Country Status (19)

Country Link
EP (1) EP0975351B1 (de)
JP (1) JP4216342B2 (de)
KR (1) KR20000070058A (de)
CN (1) CN100528222C (de)
AT (1) ATE356608T1 (de)
AU (1) AU737287B2 (de)
BR (1) BRPI9807076B8 (de)
CA (1) CA2277365C (de)
CZ (1) CZ297983B6 (de)
DE (1) DE69837324T2 (de)
EA (1) EA003128B1 (de)
HK (1) HK1025737A1 (de)
HU (1) HU226612B1 (de)
IL (2) IL119989A0 (de)
NZ (1) NZ336690A (de)
PL (1) PL193300B1 (de)
SK (1) SK284029B6 (de)
WO (1) WO1998030227A1 (de)
ZA (1) ZA98214B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1098902A4 (de) 1998-07-23 2002-07-24 Yeda Res & Dev Behandlung von autoimmunkrankheiten mittels copolymer 1 und ähnlichen copolymeren und peptiden
WO2000005249A2 (en) * 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
EP1552831B1 (de) * 1999-06-04 2009-01-07 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
CA2400374A1 (en) * 2000-02-18 2001-08-23 Adrian Gilbert Oral, nasal and pulmonary dosage formualtions of copolymer 1
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
HUP0302333A3 (en) * 2000-06-05 2005-07-28 Teva Pharma The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US7429374B2 (en) 2001-12-04 2008-09-30 Teva Pharmaceutical Industries, Ltd. Process for the measurement of the potency of glatiramer acetate
MY157727A (en) 2002-02-25 2016-07-15 Biogen Idec Inc Administration of agents for the treatment of inflamation
EP1592387A4 (de) * 2003-01-24 2009-05-06 Elan Pharm Inc Zusammensetzung für und behandlung von entmyelinierenden erkrankungen und paralyse durch verabreichung von remyelinierenden mitteln
ES2572811T3 (es) 2004-09-09 2016-06-02 Yeda Research And Development Co., Ltd. Mezclas de polipéptidos, composiciones que las contienen y procedimientos para obtener los mismos, y usos de los mismos
DK3199172T3 (en) 2009-08-20 2018-10-08 Yeda Res & Dev DOSAGE regimen for multiple sclerosis
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
ES2602977T3 (es) 2010-10-11 2017-02-23 Teva Pharmaceutical Industries Ltd. Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero
EA201490749A1 (ru) 2011-10-10 2014-09-30 Тева Фармасьютикал Индастриз Лтд. Однонуклеотидные полиморфизмы, полезные для прогнозирования клинической реакции на глатирамера ацетат
NZ630421A (en) 2012-10-10 2018-07-27 Teva Pharma Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105884866B (zh) * 2015-01-26 2021-04-20 漳州未名博欣生物医药有限公司 格拉替雷的化学合成方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
EP3603764B1 (de) * 2015-04-28 2022-03-30 Hybio Pharmaceutical Co., Ltd. Hochleistungsflüssigchromatografieverfahren
WO2018178973A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
CN110996983A (zh) 2017-06-26 2020-04-10 巴斯德研究所 清除hiv储库并降低病毒载量的治疗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins

Also Published As

Publication number Publication date
EP0975351A4 (de) 2002-05-15
SK93199A3 (en) 2000-11-07
CA2277365A1 (en) 1998-07-16
HK1025737A1 (en) 2000-11-24
ZA98214B (en) 1999-08-11
CZ243799A3 (cs) 2000-06-14
CN1249690A (zh) 2000-04-05
BR9807076B1 (pt) 2013-10-29
BR9807076A (pt) 2000-05-02
CZ297983B6 (cs) 2007-05-16
JP4216342B2 (ja) 2009-01-28
ATE356608T1 (de) 2007-04-15
SK284029B6 (sk) 2004-08-03
HUP0001917A2 (hu) 2000-10-28
DE69837324T2 (de) 2007-11-29
EA003128B1 (ru) 2003-02-27
EA199900621A1 (ru) 2000-02-28
HUP0001917A3 (en) 2001-12-28
CN100528222C (zh) 2009-08-19
JP2001511121A (ja) 2001-08-07
PL193300B1 (pl) 2007-01-31
PL334566A1 (en) 2000-03-13
IL130820A (en) 2007-03-08
HU226612B1 (en) 2009-04-28
AU737287B2 (en) 2001-08-16
NZ336690A (en) 2001-05-25
BRPI9807076B8 (pt) 2021-05-25
AU5819598A (en) 1998-08-03
EP0975351A1 (de) 2000-02-02
KR20000070058A (ko) 2000-11-25
WO1998030227A1 (en) 1998-07-16
EP0975351B1 (de) 2007-03-14
CA2277365C (en) 2011-04-12
IL119989A0 (en) 1997-04-15

Similar Documents

Publication Publication Date Title
DE69837324D1 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
DK0705100T3 (da) Terapeutiske substituerede guanidiner
DE69326250D1 (de) Neuropeptide y antagoniste
DK0591492T3 (da) Farmaceutisk præparat indeholdende et defineret lipidsystem
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
ATE271128T1 (de) Inhibitoren der il-6 aktivitaet
ATE423562T1 (de) Alpha-ketoamidhaltige multikatalytische protease inhibitoren
DK1465626T3 (da) Farmaceutiske præparater (kit) der omfatter dihydropyridinonforbindelser og et immunregulatorisk (eller et antiinflammatorisk) middel samt anvendelser deraf
MX9706913A (es) Compuestos de bis-aminacido-hidroxietilamina-sulfonamida inhibidoresde proteasan retroviral, composiciones que los contienen y ek uso de los mismos.
ATE298741T1 (de) Polyaromatische verbindungen zur behandlung von herpes-infektionen
NO974147D0 (no) Heterocykelkarbonyl aminosyre hydroksyetylamino sulfonamid retroviral protease
DE69820053D1 (de) Stör-notokord zur verminderung der symptome / behandlung von arthritis
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
ATE213233T1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
BG103632A (en) Pharmaceutical compositions containing ibuprophene and domperidon for migraine treatment
DE60113664D1 (de) Zusammensetzung zur behandlung von herzinsuffizienz
ATE309803T1 (de) Sphingomyelinase inhibitoren als wirkstoffe mit antiapoptotischer und antiseptischer wirkung
DE69831737D1 (de) Neurotrypsin
HUP0002236A2 (hu) Oldhatóvá tett szertralinkészítmények és eljárás az előállításukra
DK0722325T3 (da) Præparat til behandling eller forebyggelse af herpes
ATE141248T1 (de) Neue bis-phenyl-hexene
DK0539465T3 (da) Anvendelse af 20(R)-22-oxa-D-vitamin-analoger til fremstilling af et farmaceutisk præparat til behandling og/eller forebyggelse af hudaldring
ATE276272T1 (de) Entzündungshemmende peptide
DK0817643T3 (da) Forbindelser og præparater til administration af aktive midler
RU93055683A (ru) Ингибиторы вич-протеазы, способ их получения, их использование, композиция

Legal Events

Date Code Title Description
8364 No opposition during term of opposition